Imatinib: all 408 studies that test it

Page 1 of 5. Open to participants first (29), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)RecruitingNCT07585266Phase 3
• Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaRecruitingNCT07559370Phase 2
• Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar PustulosisNot yet recruitingNCT07530367Phase 3
• KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)RecruitingNCT07406633Phase 2
• Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal TumorRecruitingNCT07171203Phase 1
• Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingNCT06962254Phase 1
• Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)RecruitingNCT06889168Phase 1
• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT06655246Phase 1
• Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of SepsisNot yet recruitingNCT06626984Phase 1/2
• Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingNCT06124157Phase 2
• Precision Cancer Therapy in Rare CancersRecruitingNCT06119789Phase 2
• Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 DeficiencyRecruitingNCT06090669Phase 1
• Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingNCT06061094Phase 2
• Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GISTNot yet recruitingNCT05970900Phase 3
• Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC)RecruitingNCT05722795Not applicable
• Imatinib TDM in GISTRecruitingNCT05493215Phase 2
• 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High RiskRecruitingNCT05385549Phase 2
• SOLIDARITY Finland Plus Long-COVIDRecruitingNCT05220280Phase 4
• Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)RecruitingNCT05009927Phase 2
• Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal TumorsRecruitingNCT04933669Phase 2
• Asciminib Roll-over StudyRecruitingNCT04877522Phase 4
• Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant MelanomaRecruitingNCT04598009Phase 2
• Imatinib Mesylate in Combination With Pembrolizumab in Patients With MelanomaRecruitingNCT04546074Phase 1/2
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic LeukaemiaRecruitingNCT04307576Phase 3
• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic DiseaseRecruitingNCT03844360Phase 4
• Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingNCT02735707Phase 3
• Trial of Imatinib for Hospitalized Adults With COVID-19TerminatedNCT04394416Phase 3Results posted
• PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyCompletedNCT04129931Phase 2Results posted
• Imatinib for Pain in Sickle Cell AnemiaTerminatedNCT03997903Phase 1/2Results posted
• Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.CompletedNCT03578367Phase 2Results posted
• LAM Pilot Study With Imatinib MesylateCompletedNCT03131999Phase 1/2Results posted
• Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaTerminatedNCT02709083Phase 2Results posted
• Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa LoaTerminatedNCT02644525Phase 2Results posted
• The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)CompletedNCT02269267Phase 2Results posted
• BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT02257541Phase 1/2Results posted
• Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571TerminatedNCT02127372Phase 1/2Results posted
• Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in JapanCompletedNCT02042014Phase 3Results posted
• Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular ResponseTerminatedNCT01827930Phase 3Results posted
• Imatinib Treatment in Recent Onset Type 1 Diabetes MellitusCompletedNCT01781975Phase 2Results posted
• Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform NeurofibromasCompletedNCT01673009Phase 2Results posted
• Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to ImatinibCompletedNCT01593254Phase 2Results posted
• Extension to CQTI571A2102 to Evaluate Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)TerminatedNCT01392495Phase 3Results posted
• Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension ParticipantsCompletedNCT01392469Phase 3Results posted
• Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT01383447Phase 1/2Results posted
• Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT01309997Phase 2Results posted
• Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue SarcomaCompletedNCT01281865Phase 1/2Results posted
• Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal TumorsCompletedNCT01275222Phase 1/2Results posted
• Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHTCompletedNCT01151852Phase 3Results posted
• Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform NeurofibromasCompletedNCT01140360Phase 1/2Results posted
• Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)TerminatedNCT01117987Phase 3Results posted
• Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)CompletedNCT01097694Phase 2Results posted
• Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)TerminatedNCT01089595Phase 2Results posted
• Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) PatientsTerminatedNCT01031628Phase 3Results posted
• Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung CancerCompletedNCT01011075Phase 2Results posted
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaCompletedNCT00982488Phase 2Results posted
• Treatment of Older Adults With Acute Lymphoblastic LeukemiaCompletedNCT00973752Phase 2Results posted
• CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT00955916Phase 2Results posted
• Gleevec and Gemzar in Patients With Epithelial Ovarian CancerCompletedNCT00928642Phase 2Results posted
• Imatinib (QTI571) in Pulmonary Arterial HypertensionCompletedNCT00902174Phase 3Results posted
• New Individualized Therapy Trial for Metastatic Colorectal CancerCompletedNCT00867334Phase 1/2Results posted
• Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)CompletedNCT00867113Phase 2Results posted
• Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate CancerTerminatedNCT00861471Phase 1/2Results posted
• Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian OriginTerminatedNCT00840450Phase 2Results posted
• Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host DiseaseCompletedNCT00702689Phase 2Results posted
• Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CMLCompletedNCT00702403Phase 1/2Results posted
• Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's LymphomaCompletedNCT00684411Phase 2Results posted
• Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic FibrosisCompletedNCT00677092Phase 2Results posted
• Study of Temzolomide and Gleevec in Advanced MelanomaTerminatedNCT00667953Phase 1/2Results posted
• Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)CompletedNCT00615927Phase 2Results posted
• Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic SclerosisCompletedNCT00613171Phase 2Results posted
• Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) PatientsTerminatedNCT00585221Phase 2Results posted
• Safety Study of Gleevec® in Children With Pulmonary HypertensionTerminatedNCT00583115Phase 2Results posted
• Imatinib Mesylate (Gleevec) in the Treatment of Systemic SclerosisCompletedNCT00555581Phase 2Results posted
• A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic SclerosisCompletedNCT00512902Phase 1/2Results posted
• Gleevec Study for Patients With Ovarian CancerCompletedNCT00510653Phase 2Results posted
• Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received ChemotherapyCompletedNCT00509093Phase 2Results posted
• Imatinib in Systemic SclerosisCompletedNCT00506831Phase 1/2Results posted
• Gleevec/Taxol for Patients With Uterine Papillary Serous CarcinomaTerminatedNCT00506779Phase 1/2Results posted
• Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate CancerCompletedNCT00500110Phase 2Results posted
• Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML PatientsTerminatedNCT00499889Phase 2Results posted
• Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell CancerCompletedNCT00485485Phase 2Results posted
• Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial HypertensionCompletedNCT00477269Phase 2/3Results posted
• ALL Adult Consortium Trial: Adult ALL TrialCompletedNCT00476190Phase 2Results posted
• A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)CompletedNCT00471497Phase 3Results posted
• Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2Results posted
• Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic LeukemiaCompletedNCT00458848Phase 2Results posted
• Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate CancerCompletedNCT00427999Phase 2Results posted
• Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaCompletedNCT00424515Phase 2Results posted
• Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)CompletedNCT00424385Phase 1Results posted
• TALL-104 and Gleevec in Chronic Myelogenous Leukemia PatientsTerminatedNCT00415909Phase 2Results posted
• Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00408460Phase 2Results posted
• A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib TherapyTerminatedNCT00362466Phase 3Results posted
• Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive MeningiomaCompletedNCT00354913Phase 2Results posted
• Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast CancerCompletedNCT00338728Phase 2Results posted
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaCompletedNCT00333840Phase 3Results posted
• Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney CancerCompletedNCT00331409Phase 2Results posted
• Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung CancerTerminatedNCT00323362Phase 2Results posted

← Imatinib overview